These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 23259441)

  • 1. Treprostinil for the treatment of pulmonary arterial hypertension.
    Torres F; Rubin LJ
    Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
    LeVarge BL; Channick RN
    Expert Rev Respir Med; 2012 Jun; 6(3):255-65. PubMed ID: 22788940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
    Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ
    Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
    Channick RN; Olschewski H; Seeger W; Staub T; Voswinckel R; Rubin LJ
    J Am Coll Cardiol; 2006 Oct; 48(7):1433-7. PubMed ID: 17010807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension.
    Gessler T; Seeger W; Schmehl T
    Ther Adv Respir Dis; 2011 Jun; 5(3):195-206. PubMed ID: 21300738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treprostinil for pulmonary hypertension.
    Vachiéry JL; Naeije R
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):183-91. PubMed ID: 15151467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
    Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
    J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
    Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ
    J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subcutaneous treprostinil in pulmonary arterial hypertension: Practical considerations.
    Mathier MA; McDevitt S; Saggar R
    J Heart Lung Transplant; 2010 Nov; 29(11):1210-7. PubMed ID: 20855220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
    Poms A; Kingman M
    Crit Care Nurse; 2011 Dec; 31(6):e1-10. PubMed ID: 22135338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
    J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension.
    Ferrantino M; White RJ
    Expert Opin Pharmacother; 2011 Nov; 12(16):2583-93. PubMed ID: 21988216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of treprostinil in the management of pulmonary hypertension.
    Skoro-Sajer N; Lang I
    Am J Cardiovasc Drugs; 2008; 8(4):213-7. PubMed ID: 18690755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension.
    Voswinckel R; Reichenberger F; Enke B; Kreckel A; Krick S; Gall H; Schermuly RT; Grimminger F; Rubin LJ; Olschewski H; Seeger W; Ghofrani HA
    Pulm Pharmacol Ther; 2008 Oct; 21(5):824-32. PubMed ID: 18657627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension.
    McLaughlin VV; Palevsky HI
    Clin Chest Med; 2013 Dec; 34(4):825-40. PubMed ID: 24267307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
    Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
    J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of oral treprostinil sustained release tablets during chronic administration to patients with pulmonary arterial hypertension.
    White RJ; Torres F; Allen R; Jerjes C; Pulido T; Yehle D; Howell M; Laliberte K; Marier JF; Tapson VF
    J Cardiovasc Pharmacol; 2013 Jun; 61(6):474-81. PubMed ID: 23328389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral treprostinil for the treatment of pulmonary arterial hypertension.
    de Lartigue J
    Drugs Today (Barc); 2014 Aug; 50(8):557-65. PubMed ID: 25187906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled treprostinil: a therapeutic review.
    Channick RN; Voswinckel R; Rubin LJ
    Drug Des Devel Ther; 2012; 6():19-28. PubMed ID: 22291467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
    Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
    J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.